Consult an Expert
Trademark
Design Registration
Consult an Expert
Trademark
Copyright
Patent
Infringement
Design Registration
More
Consult an Expert
Consult an Expert
Trademark
Design Registration
Login
CFXON
BIOIMMENSE BIOTECHNOLOGY PRIVATE LIMITED
CFXON is a WORD Trademark filed on Nov 20, 2021 in MAHARASHTRA through India IP Office.The Trademark is registered to BIOIMMENSE BIOTECHNOLOGY PRIVATE LIMITED and was filed by NEWTON REGINALD[25853].
CFXON BIOIMMENSE BIOTECHNOLOGY PRIVATE LIMITED Trademark Information
Application ID
5216732
Status
Refused
Date of Application
Nov 20, 2021
Classes
5
Proprietor(s)
BIOIMMENSE BIOTECHNOLOGY PRIVATE LIMITED
Attorney
NEWTON REGINALD[25853]
No 6, Dhanammal Street Spurtank Road Chetpet Chennai - 600031
Type
WORD
Registration State
MAHARASHTRA
Country
India
IP Office
MUMBAI
Used Since
Proposed to be used
Uploaded Documents
1
TM-A(TRADE MARKS APPLICATION)
Nov 20, 2021
2
Reply to Exam Report (MIS-R)
Jan 24, 2022
3
Documents in support of Show cause Hearing (SCH)
Feb 01, 2024
4
Authorization Letter
Feb 01, 2024
Correspondence and Notices
1
EXAMINATION REPORT
12688369
Dec 21, 2021
2
Hearing Notice (Show Cause)
17030318
Jan 04, 2024
3
Tribunal Refused Notice for : 5216732
17326897
6528165
Feb 06, 2024
FAQs
Our experts are here to assist you in finding a similar trademark.
Talk To Experts
Calculators
Downloads
By continuing past this page, you agree to our Terms of Service , Cookie Policy , Privacy Policy and Refund Policy © - Uber9 Business Process Services Private Limited. All rights reserved.
Uber9 Business Process Services Private Limited, CIN - U74900TN2014PTC098414, GSTIN - 33AABCU7650C1ZM, Registered Office Address - F-97, Newry Shreya Apartments Anna Nagar East, Chennai, Tamil Nadu 600102, India.
Please note that we are a facilitating platform enabling access to reliable professionals. We are not a law firm and do not provide legal services ourselves. The information on this website is for the purpose of knowledge only and should not be relied upon as legal advice or opinion.
